A PYMNTS Company

US: California Supreme Court revives generic Cipro antitrust suit

By  |  May 7, 2015

The California Supreme Court on Thursday revived a class-action lawsuit that accuses Bayer of paying another drug company to delay introducing a generic version of a Bayer antibiotic.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The practice is known as “pay to delay” and can violate antitrust law, according to a 2013 US Supreme Court decision.

    The unanimous ruling by the state’s highest court was aimed at a settlement reached by Bayer, the holder of a patent on Cipro, and Barr Laboratories Inc., which wanted to introduce a generic version of the popular antibiotic and challenged Bayer’s patent.

    Under the settlement, Bayer agreed to pay Barr $398.1 million, and Barr agreed to postpone the marketing of its generic.

    The settlement sparked several antitrust lawsuits, including nine class-action suits filed by California consumers.

     

    Full content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.